
AbbVie to Acquire Apogee Therapeutics in US$10.9 Billion Deal as Immunology Business Continues to Expand
AbbVie has agreed to acquire Apogee Therapeutics in an all-cash transaction valued at approximately US$10.9 billion, offering US$135.11 per share as the pharmaceutical company continues








